JP2009506985A - 腫瘍の診断及び治療のための標的としてのプレキシンｄ１ - Google Patents

腫瘍の診断及び治療のための標的としてのプレキシンｄ１ Download PDF

Info

Publication number
JP2009506985A
JP2009506985A JP2008521907A JP2008521907A JP2009506985A JP 2009506985 A JP2009506985 A JP 2009506985A JP 2008521907 A JP2008521907 A JP 2008521907A JP 2008521907 A JP2008521907 A JP 2008521907A JP 2009506985 A JP2009506985 A JP 2009506985A
Authority
JP
Japan
Prior art keywords
plexin
tumor
use according
binding
molecule
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2008521907A
Other languages
English (en)
Japanese (ja)
Other versions
JP2009506985A5 (https=
Inventor
レーンデルス，ウイルヘルム・ペトルス・ヨハネス
ローデインク，イルス
ラーツ，ヨゼフ・マリア・ヘンドリツク
Original Assignee
ステイヒテイング・カソリーケ・ユニベルシタイト
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ステイヒテイング・カソリーケ・ユニベルシタイト filed Critical ステイヒテイング・カソリーケ・ユニベルシタイト
Publication of JP2009506985A publication Critical patent/JP2009506985A/ja
Publication of JP2009506985A5 publication Critical patent/JP2009506985A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
    • A61K47/6817—Toxins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1018—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/22—Immunoglobulins specific features characterized by taxonomic origin from camelids, e.g. camel, llama or dromedary
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Toxicology (AREA)
  • Cell Biology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Mycology (AREA)
  • Optics & Photonics (AREA)
  • Physics & Mathematics (AREA)
  • Oncology (AREA)
  • Microbiology (AREA)
  • Dermatology (AREA)
  • Rheumatology (AREA)
  • Vascular Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Urology & Nephrology (AREA)
  • Pulmonology (AREA)
JP2008521907A 2005-07-21 2006-07-20 腫瘍の診断及び治療のための標的としてのプレキシンｄ１ Pending JP2009506985A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP05076675 2005-07-21
PCT/EP2006/007241 WO2007009816A2 (en) 2005-07-21 2006-07-20 Plexin d1 as a target for tumor diagnosis and therapy

Publications (2)

Publication Number Publication Date
JP2009506985A true JP2009506985A (ja) 2009-02-19
JP2009506985A5 JP2009506985A5 (https=) 2009-09-03

Family

ID=37115996

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2008521907A Pending JP2009506985A (ja) 2005-07-21 2006-07-20 腫瘍の診断及び治療のための標的としてのプレキシンｄ１

Country Status (12)

Country Link
US (4) US20100119445A1 (https=)
EP (1) EP1907420B1 (https=)
JP (1) JP2009506985A (https=)
CN (1) CN101287758A (https=)
AU (1) AU2006271880A1 (https=)
BR (1) BRPI0613425A2 (https=)
CA (1) CA2615744C (https=)
DK (1) DK1907420T3 (https=)
ES (1) ES2632360T3 (https=)
IL (1) IL188688A0 (https=)
PL (1) PL1907420T3 (https=)
WO (1) WO2007009816A2 (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018190365A1 (ja) * 2017-04-12 2018-10-18 国立大学法人九州大学 神経障害性疼痛マーカー及びその使用

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090181035A1 (en) * 2008-01-10 2009-07-16 Genentech, Inc. Plexind1 agonists and their use
US8512944B2 (en) * 2008-08-27 2013-08-20 Oncotherapy Science, Inc. PRMT1 for target genes of cancer therapy and diagnosis
CN101914542B (zh) * 2009-04-28 2013-03-06 中国科学院化学研究所 用于不同亚型非小细胞肺癌分型的一种核酸适体及其筛选方法
EP2385121A1 (en) * 2010-05-06 2011-11-09 Netris Pharma Antagonists of Sema3E/PlexinD1 interaction as anti-cancer agents
EP2487242A1 (en) 2011-02-09 2012-08-15 Ruprecht-Karls-Universität Heidelberg B-type plexin antagonists and uses thereof
CA2912801A1 (en) * 2013-05-17 2014-11-20 Medimmune, Llc Receptors for b7-h4
US11066462B2 (en) 2014-12-11 2021-07-20 Citryll B.V. Method for the treatment of idiopathic pulmonary fibrosis
CN106967789A (zh) * 2017-01-26 2017-07-21 上海长海医院 一种前列腺癌标志物plxna1及其应用
EP3693380A1 (en) 2019-02-11 2020-08-12 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Dual inhibition of plexin-b1 and plexin-b2
CN117659171B (zh) * 2022-09-07 2024-10-22 东莞市朋志生物科技有限公司 抗HBeAg抗体或其功能性片段、检测HBeAg的试剂和试剂盒
CN116459356B (zh) * 2023-04-24 2024-03-19 中国人民解放军总医院第一医学中心 用于动脉粥样硬化斑块早期预警和动态监测的多模态分子成像纳米探针及其应用

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001014420A2 (en) * 1999-08-25 2001-03-01 University Of Torino Novel members of the plexin family and uses thereof
WO2005056791A1 (ja) * 2003-10-30 2005-06-23 Kazusa Dna Research Institute Foundation 新規PlexinポリペプチドとそれをコードするＤＮＡ、及びその用途

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6020145A (en) * 1989-06-30 2000-02-01 Bristol-Myers Squibb Company Methods for determining the presence of carcinoma using the antigen binding region of monoclonal antibody BR96
US7442776B2 (en) * 1999-10-08 2008-10-28 Young David S F Cancerous disease modifying antibodies
WO2001090190A2 (en) * 2000-05-26 2001-11-29 National Research Council Of Canada Single-domain antigen-binding antibody fragments derived from llama antibodies
EP2236614A3 (en) * 2002-08-15 2011-01-26 Genzyme Corporation Brain endothelial cell expression patterns
SE0203137D0 (sv) * 2002-10-24 2002-10-24 Karolinska Innovations Ab Drug target in cancer therapy
AU2003292231A1 (en) * 2002-12-12 2004-06-30 Novartis Ag Methods for diagnosing and treating schizophrenia
CA2519630A1 (en) * 2003-03-20 2004-10-07 Dana-Farber Cancer Institute, Inc. Gene expression in breast cancer
DE102004037860A1 (de) * 2004-08-04 2006-03-16 Friedrich-Alexander-Universität Erlangen-Nürnberg Turmormarker zur Diagnose von Karzinomen und/oder davon abstammender Metastasen

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001014420A2 (en) * 1999-08-25 2001-03-01 University Of Torino Novel members of the plexin family and uses thereof
WO2005056791A1 (ja) * 2003-10-30 2005-06-23 Kazusa Dna Research Institute Foundation 新規PlexinポリペプチドとそれをコードするＤＮＡ、及びその用途

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018190365A1 (ja) * 2017-04-12 2018-10-18 国立大学法人九州大学 神経障害性疼痛マーカー及びその使用
JPWO2018190365A1 (ja) * 2017-04-12 2020-05-14 国立大学法人九州大学 神経障害性疼痛マーカー及びその使用
JP7067800B2 (ja) 2017-04-12 2022-05-16 国立大学法人九州大学 神経障害性疼痛マーカー及びその使用

Also Published As

Publication number Publication date
DK1907420T3 (en) 2017-07-17
EP1907420B1 (en) 2017-04-05
CA2615744C (en) 2018-03-27
US20100119445A1 (en) 2010-05-13
US9988449B2 (en) 2018-06-05
CA2615744A1 (en) 2007-01-25
PL1907420T3 (pl) 2017-09-29
WO2007009816A2 (en) 2007-01-25
US9422358B2 (en) 2016-08-23
BRPI0613425A2 (pt) 2012-10-30
US20120321554A1 (en) 2012-12-20
US20160311900A1 (en) 2016-10-27
AU2006271880A1 (en) 2007-01-25
WO2007009816A3 (en) 2007-03-29
CN101287758A (zh) 2008-10-15
IL188688A0 (en) 2008-08-07
US20180319882A1 (en) 2018-11-08
ES2632360T3 (es) 2017-09-12
EP1907420A2 (en) 2008-04-09

Similar Documents

Publication Publication Date Title
US9988449B2 (en) Plexin D1 as a target for tumor diagnosis and therapy
CN103073641B (zh) 在体内具有抗肿瘤活性的抗人Dlk-1抗体
JP6232646B2 (ja) 癌診断に有用なクローディン１８．２に対する抗体
CN101432307B (zh) 显示cd44表面表达的细胞的细胞毒性介导
JP2017525354A (ja) 高親和性ｐｄ−１薬剤とその使用方法
KR20100017169A (ko) Ｆｇｆ２１-관련 장애의 치료, 진단 및 검출 방법
JP2010530735A (ja) 細胞内のｐｒｌ−１ポリペプチドまたはｐｒｌ−３ポリペプチドに結合する抗体
CN101501073A (zh) 抗体制备方法
JP2013522167A (ja) ｕＰＡＲ結合剤及びその使用方法
Roodink et al. Plexin D1 expression is induced on tumor vasculature and tumor cells: a novel target for diagnosis and therapy?
AU2012296362A1 (en) Antibodies that bind integrin alpha-v beta-8
KR20200040784A (ko) 암 진단에 유용한 항체
BRPI0710616A2 (pt) métodos para tratar, diagnosticar ou detectar cáncer
JP2012508027A (ja) Ｎ−カドヘリンに対する完全ヒト抗体
Putelli et al. A fibrin-specific monoclonal antibody from a designed phage display library inhibits clot formation and localizes to tumors in vivo
AU2011306816A1 (en) Anti-ephrin-B2 antibody and use thereof
CA2585719A1 (en) Tumor association of mdl-1 and methods
HK1124346A (en) Plexin d1 as a target for tumor diagnosis and therapy
MX2008000919A (en) Plexin d1 as a target for tumor diagnosis and therapy
WO2010037856A2 (en) DYNACTIN-1/p150glued AS A TARGET FOR TUMOR DIAGNOSIS AND THERAPY AND A METHOD FOR IDENTIFYING TARGETABLE DISEASE-RELATED PROTEINS
JP2012515158A (ja) 癌の予防・治療剤
HK40119074A (zh) 用於癌症诊断的抗体
HK40085652B (zh) 用於癌症诊断的抗体
JP2013543379A (ja) 操作されたヒトエンドシアリン発現齧歯動物

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20090716

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20090716

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20111101

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20120126

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20120202

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20120626